New hope for rare lung cancer? poziotinib trial targets HER2 mutations

NCT ID NCT05378763

Terminated Disease control Sponsor: Spectrum Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 study compares the experimental drug poziotinib to the standard chemotherapy docetaxel in 268 people with advanced non-small cell lung cancer that has a specific HER2 mutation. Participants must have already tried at least one prior treatment. The main goal is to see if poziotinib can delay cancer growth longer than docetaxel. The trial is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: poziotinib
What this could lead to: If successful, poziotinib could offer a new targeted treatment option for people with a specific type of lung cancer that has few approved therapies.
What could go wrong: The trial is currently suspended, and it's a head-to-head comparison against an existing chemotherapy. Success is not guaranteed, and side effects from poziotinib may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC

Contacts and locations

Locations

Bond Clinic, P.A.

Winter Haven, Florida, 33880, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.